Abstract
Visceral obesity is characterized by increased risk of cardiovascular disease as well as higher incidence of malignancies, including colorectal cancer (CRC), although the mechanisms linking excess adiposity with cancer are only partly characterized. Visceral obesity is currently acknowledged as a chronic inflammatory disorder and a growing body of evidence demonstrates the interconnections between obesity-related secretion pattern of adipo/cytokines and CRC. Specific molecules derived from the visceral adipose tissue (VAT), including adiponectin, leptin and resistin, are able to establish a positive feedback loop, thus increasing the proinflammatory and insulin resistant state and promoting tumorigenesis. Interestingly, these molecules have emerged as novel prognostic factors and therapeutic targets. This review will focus on current molecular and clinical evidence linking VAT-related inflammation to CRC initiation and progression, and summarize the role of dietary factors and lifestyle interventions aimed at promoting weight control and physical activity on CRC prevention and prognosis.
Keywords: Adipokines, colorectal cancer, inflammation, insulin resistance, visceral obesity, white adipose tissue, gut microbiota, liver inflammation, free fatty acid, non-alcoholic steatohepatitis
Current Medicinal Chemistry
Title:Obesity-Driven Inflammation and Colorectal Cancer
Volume: 19 Issue: 34
Author(s): N. Vazzana, S. Riondino, V. Toto, F. Guadagni, M. Roselli, G. Davì and P. Ferroni
Affiliation:
Keywords: Adipokines, colorectal cancer, inflammation, insulin resistance, visceral obesity, white adipose tissue, gut microbiota, liver inflammation, free fatty acid, non-alcoholic steatohepatitis
Abstract: Visceral obesity is characterized by increased risk of cardiovascular disease as well as higher incidence of malignancies, including colorectal cancer (CRC), although the mechanisms linking excess adiposity with cancer are only partly characterized. Visceral obesity is currently acknowledged as a chronic inflammatory disorder and a growing body of evidence demonstrates the interconnections between obesity-related secretion pattern of adipo/cytokines and CRC. Specific molecules derived from the visceral adipose tissue (VAT), including adiponectin, leptin and resistin, are able to establish a positive feedback loop, thus increasing the proinflammatory and insulin resistant state and promoting tumorigenesis. Interestingly, these molecules have emerged as novel prognostic factors and therapeutic targets. This review will focus on current molecular and clinical evidence linking VAT-related inflammation to CRC initiation and progression, and summarize the role of dietary factors and lifestyle interventions aimed at promoting weight control and physical activity on CRC prevention and prognosis.
Export Options
About this article
Cite this article as:
Vazzana N., Riondino S., Toto V., Guadagni F., Roselli M., Davì G. and Ferroni P., Obesity-Driven Inflammation and Colorectal Cancer, Current Medicinal Chemistry 2012; 19 (34) . https://dx.doi.org/10.2174/092986712804143349
DOI https://dx.doi.org/10.2174/092986712804143349 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Correlation Between <i>BCL2</i> and <i>Mcl1</i> Single Nucleotide Polymorphisms and Chemotherapy Response in Jordanian Patients with Colorectal Cancer
Current Pharmaceutical Biotechnology Prostaglandins Pathway as a Possible Biological Link Between Cancer and Major Depression
Current Angiogenesis (Discontinued) Current Perspectives on the Role of Nrf2 in 5-Fluorouracil Resistance in Colorectal Cancer
Anti-Cancer Agents in Medicinal Chemistry Cellular Senescence in the Development and Treatment of Cancer
Current Pharmaceutical Design Angiopoietin-2 Axis Inhibitors: Current Status and Future Considerations for Cancer Therapy
Current Angiogenesis (Discontinued) Monoclonal Antibody Therapy in Haematological Malignancies
Current Clinical Pharmacology In Silico Approach to Finding New Active Compounds from Histone Deacetylase (HDAC) Family
Current Pharmaceutical Design Therapeutic and Diagnostic Applications of Nanoparticles
Current Drug Targets Recent Trends in Targeted Anticancer Prodrug and Conjugate Design
Current Medicinal Chemistry Commonalities and Differences Between Crohns Disease and Ulcerative Colitis: The Genetic Clues to their Interpretation
Inflammation & Allergy - Drug Targets (Discontinued) Accessing Cancer Metabolic Pathways by the Use of Microarray Technology
Current Pharmaceutical Design Evaluation of Direct Effect of Testosterone on NGEP and LM O1 Expression in LNCaP Prostate Cancer Cells
Current Biomarkers (Discontinued) Synthesis and Antiproliferative Evaluation of Hybrids of Indolin-2-one and Quinazoline-4(3H)-one Linked via Imine Bond
Letters in Drug Design & Discovery CYP17 Inhibitors for Prostate Cancer Treatment – An Update
Current Medicinal Chemistry Targeting BMP9-Promoted Human Osteosarcoma Growth by Inactivation of Notch Signaling
Current Cancer Drug Targets Kisspeptin: Paving the Way to a New Therapeutic Avenue in Reproduction
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Corneal Neovascularization: Molecular Events and Therapeutic Options
Recent Patents on Inflammation & Allergy Drug Discovery Targeted Cancer Immunotherapy Using Ligands of the Tumor Necrosis Factor Super-Family
Current Drug Targets Diastereoselective Addition of Organometallic Reagents to Diimines Derived from (R,R)-1,2-Diaminocyclohexane and Aromatic Aldehydes
Letters in Organic Chemistry CXCR4 and CXCL12 Expression in Rectal Tumors of Stage IV Patients Before and After Local Radiotherapy and Systemic Neoadjuvant Treatment
Current Pharmaceutical Design